GO:1905906 regulation of amyloid fibril formation: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1905906 (regulation of amyloid fibril formation) is a biological process that modulates the frequency, rate or extent of amyloid fibril assembly.
• Amyloid fibril formation is a nucleation-dependent polymerization process that can be regulated by charge, pH, mutations, and post-translational modifications [1,2].
• Key proteins involved include α-synuclein, p16(INK4A), PMEL, serum amyloid A, parathyroid hormone, and RNA-binding proteins [1,2,3,5,6,7].
• Dysregulation of amyloid fibril formation is linked to neurodegeneration, cancer, and systemic amyloidosis [1,2,6].
• CRISPR knockout, point mutation, knock-in, and overexpression models are essential to dissect causal roles of regulatory genes.
• EDITGENE provides end-to-end CRISPR services to study amyloid fibril regulation, from library screening to bioinformatics.
Description
Amyloid fibrils are ordered, β-sheet-rich protein aggregates that underlie numerous human disorders, including neurodegenerative diseases and systemic amyloidoses [1,6]. The process by which these fibrils assemble is not spontaneous but is tightly controlled by a network of regulatory factors that influence nucleation, elongation, and fibril stability. GO:1905906, regulation of amyloid fibril formation, captures any process that modulates the frequency, rate or extent of amyloid fibril formation. Understanding this regulation is critical because even subtle changes in the cellular environment—such as charge alterations, oxidative modifications, or the presence of pro-sequences—can tip the balance toward pathological aggregation [1,2,7]. Research over the past decade has revealed that amyloid fibril formation is regulated at multiple levels: intrinsic protein properties (e.g., charge, sequence), post-translational modifications (e.g., cysteine oxidation), interactions with other biomolecules (e.g., RNA, lipids), and cellular quality-control machinery [1,2,5]. For example, the charge state of α-synuclein directly influences its aggregation kinetics, with charge-neutralizing mutations accelerating fibril formation. Similarly, oxidative modification of p16(INK4A) triggers its amyloidogenic conversion, linking redox biology to tumor suppressor inactivation. These findings underscore the need for precise experimental models to dissect regulatory mechanisms. This article provides a comprehensive overview of GO:1905906, covering its definition, biological significance, key genes, regulatory mechanisms, disease connections, and state-of-the-art research methods. It is designed for researchers seeking to understand how amyloid fibril formation is controlled and how to study it using CRISPR-based approaches and other advanced technologies.
regulation of amyloid fibril formation At A Glance
| GO ID | GO:1905906 |
|---|---|
| GO term | regulation of amyloid fibril formation |
| Ontology | biological_process |
| Synonym | regulation of amyloid fibril assembly; regulation of amyloid structure assembly; regulation of amyloid structure formation |
| Major function | Modulates the frequency, rate or extent of amyloid fibril formation |
| Related processes | Protein aggregation, amyloidosis, neurodegeneration, cancer |
| Key regulators | α-synuclein, p16(INK4A), PMEL, serum amyloid A, parathyroid hormone, RNA-binding proteins |
| Disease relevance | Parkinson's disease, cancer, systemic amyloidosis, pigmentation disorders |
What Is GO:1905906?
GO:1905906, regulation of amyloid fibril formation, is defined as any process that modulates the frequency, rate or extent of amyloid fibril formation. Amyloid fibril formation itself is the ordered aggregation of proteins into insoluble, β-sheet-rich fibrils. Regulation can occur at any step—nucleation, elongation, fragmentation, or clearance—and can be mediated by changes in protein concentration, post-translational modifications, interactions with chaperones or other molecules, or environmental factors such as pH and ionic strength [1,2,6].
Why Is regulation of amyloid fibril formation Important in Cell Biology?
Regulation of amyloid fibril formation is fundamentally important because amyloid fibrils are hallmarks of dozens of debilitating human diseases, and the ability to modulate their formation could lead to therapeutic interventions [1,2,6]. Moreover, amyloid fibrils can serve normal biological functions, such as in melanosome biogenesis, where PMEL forms functional amyloid. Thus, understanding the regulatory mechanisms is essential for both disease treatment and basic cell biology.
• Amyloid fibrils are central to neurodegenerative diseases such as Parkinson's disease, where α-synuclein aggregation is a key pathological feature.
• The tumor suppressor p16(INK4A) can form amyloid fibrils upon oxidative stress, linking amyloid regulation to cancer biology.
• PMEL amyloid fibrils are essential for melanin synthesis and pigmentation, representing a functional amyloid system.
• Serum amyloid A (SAA) amyloidosis is a complication of chronic inflammatory diseases, and its fibril formation is influenced by N-terminal modifications.
• Parathyroid hormone (PTH) has a pro-sequence that prevents premature amyloid fibril formation, highlighting the role of pro-peptides in regulation.
• RNA-binding proteins can undergo phase separation and form amyloid-like fibrils, connecting amyloid regulation to RNA metabolism.
• Cereal proteins can form amyloid fibrils, and nonthermal processing can regulate this process, with implications for food science.
• Diffusing protein binders can be engineered to target intrinsically disordered proteins and modulate their aggregation.
• Understanding amyloid regulation can inform the design of inhibitors or promoters of fibril formation for therapeutic or biotechnological applications [1,8].
• CRISPR-based models enable precise dissection of regulatory genes in amyloid formation pathways.
What Happens During regulation of amyloid fibril formation?
Nucleation and the Lag Phase
In simple terms: The first step is a slow 'waiting period' where proteins cluster into a tiny seed, which is the hardest part of fibril formation.
Amyloid fibril formation typically begins with a nucleation phase, also called the lag phase, during which monomeric proteins associate into transient oligomers that eventually form a stable nucleus. This step is highly unfavorable and is a major target for regulation. For α-synuclein, charge regulation plays a critical role: the protein's net charge and charge distribution affect the rate of nucleation, with charge-neutralizing conditions accelerating the process. Similarly, the pro-sequence of parathyroid hormone prevents premature nucleation by keeping the protein in a soluble, non-amyloidogenic state until it is cleaved. Regulatory factors can either stabilize the monomer, destabilize the nucleus, or promote the formation of on-pathway oligomers.
Elongation and Fibril Growth
In simple terms: Once a seed exists, it acts like a template, rapidly adding more protein molecules to grow into long fibrils.
After nucleation, fibrils elongate by recruiting monomers to the ends of the growing fibril. This step is often diffusion-limited and can be regulated by the concentration of available monomer, the presence of chaperones, or post-translational modifications. For example, cysteine oxidation of p16(INK4A) triggers a conformational change that promotes fibril elongation, linking oxidative stress to amyloid formation. In the case of serum amyloid A, N-terminal modifications such as truncation or extension can alter elongation kinetics, potentially affecting amyloidogenicity. Regulatory processes that sequester monomers or cap fibril ends can effectively inhibit elongation.
Secondary Nucleation and Fragmentation
In simple terms: Fibrils can break into smaller pieces or spawn new seeds on their surface, amplifying the aggregation process.
Secondary nucleation occurs when existing fibrils catalyze the formation of new nuclei on their surface, leading to exponential growth. Fragmentation, the breaking of fibrils into smaller fragments, also generates new ends for elongation. These processes are critical for the spread of amyloid pathology. Regulation of secondary nucleation and fragmentation can be achieved by molecules that stabilize fibril structure or by mechanical forces. For instance, the presence of RNA-binding proteins can promote phase separation and subsequent fibrillization, potentially through secondary nucleation mechanisms. Understanding these steps is essential for developing therapies that target amyloid propagation.
Phase Separation and Liquid-to-Solid Transition
In simple terms: Proteins can first form liquid droplets, and over time these droplets can harden into amyloid fibrils.
Liquid-liquid phase separation (LLPS) has emerged as a key regulatory step in amyloid fibril formation. RNA-binding proteins such as FUS and hnRNPA1 can undergo LLPS, forming liquid droplets that mature into gel-like or solid amyloid fibrils. This transition is regulated by factors such as RNA concentration, salt, and post-translational modifications. The regulation of LLPS therefore directly impacts amyloid fibril formation. Diffusing protein binders can be engineered to target intrinsically disordered proteins and modulate their phase behavior, offering a tool to study and regulate this process.
Cellular Clearance and Chaperone Regulation
In simple terms: Cells have quality-control systems that can remove or refold amyloid-prone proteins, acting as a brake on fibril formation.
Cells employ molecular chaperones and degradation pathways (e.g., proteasome, autophagy) to prevent the accumulation of amyloidogenic proteins. Regulation of amyloid fibril formation therefore includes chaperone-mediated inhibition of nucleation and elongation, as well as clearance of prefibrillar oligomers. For example, the pro-sequence of PTH may facilitate proper folding and prevent premature aggregation until the hormone is secreted. In pigmentation, PMEL amyloid formation is tightly regulated within melanosomes, and defects in this regulation can lead to pigmentation disorders. These cellular mechanisms are critical for maintaining proteostasis.
Key Genes Involved in GO:1905906 regulation of amyloid fibril formation
The following genes and proteins are key players in the regulation of amyloid fibril formation, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SNCA | Encodes α-synuclein; charge and mutations regulate fibril formation | Parkinson's disease, Lewy body dementia |
| CDKN2A | Encodes p16(INK4A); cysteine oxidation triggers amyloid fibril formation | Cancer, aging, redox biology |
| PMEL | Forms functional amyloid fibrils in melanosomes | Pigmentation, melanosome biology |
| SAA1 | Serum amyloid A; N-terminal modifications influence fibril formation | Systemic amyloidosis, inflammation |
| PTH | Parathyroid hormone; pro-sequence prevents premature fibril formation | Endocrine disorders, protein folding |
| FUS | RNA-binding protein; undergoes phase separation and fibrillization | ALS, neurodegeneration |
| HNRNPA1 | RNA-binding protein; forms amyloid-like fibrils | ALS, neurodegeneration |
| TARDBP | Encodes TDP-43; forms amyloid fibrils in ALS | ALS, frontotemporal dementia |
| CRISPR-engineered binders | Diffusing protein binders to intrinsically disordered proteins | Tool for studying and regulating amyloid formation |
| Cereal proteins | Plant proteins that can form amyloid fibrils | Food science, nonthermal processing |
| Lysozyme | Model protein for amyloid fibril formation | Systemic amyloidosis |
| Transthyretin | Forms amyloid fibrils in transthyretin amyloidosis | Cardiomyopathy, neuropathy |
| Aβ peptide | Amyloid beta; forms fibrils in Alzheimer's disease | Alzheimer's disease |
| Tau | Microtubule-associated protein; forms amyloid fibrils | Alzheimer's disease, tauopathies |
| Islet amyloid polypeptide | Forms amyloid in type 2 diabetes | Diabetes |
| β2-microglobulin | Forms amyloid fibrils in dialysis-related amyloidosis | Dialysis complications |
| Immunoglobulin light chain | Forms amyloid fibrils in AL amyloidosis | Plasma cell disorders |
How Is regulation of amyloid fibril formation Regulated?
Regulation of amyloid fibril formation is itself a highly regulated process. Key regulatory mechanisms include: (1) charge regulation, as demonstrated for α-synuclein, where changes in net charge alter nucleation and elongation rates; (2) oxidative modifications, such as cysteine oxidation of p16(INK4A), which triggers fibril formation; (3) proteolytic processing, as seen with parathyroid hormone, where the pro-sequence prevents premature aggregation; (4) phase separation, where RNA-binding proteins form liquid droplets that can mature into fibrils, regulated by RNA and salt; and (5) cellular chaperones and degradation pathways that maintain proteostasis. Additionally, nonthermal processing can regulate amyloid fibril formation in cereal proteins, highlighting environmental influences.
regulation of amyloid fibril formation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SNCA | Parkinson's disease | Knockout or point-mutation (A53T) in SH-SY5Y or iPSC-derived neurons |
| CDKN2A | Cancer, oxidative stress | Knock-in of cysteine mutants in cancer cell lines |
| PMEL | Pigmentation disorders | Knockout in melanocytes, overexpression of PMEL mutants |
| SAA1 | AA amyloidosis | Knock-in of N-terminal variants in hepatocytes |
| FUS | ALS | Knock-in of ALS-associated mutations in motor neurons |
Neurodegenerative Diseases
Amyloid fibril formation is a hallmark of many neurodegenerative diseases. In Parkinson's disease, α-synuclein aggregates into Lewy bodies, and charge alterations or mutations in SNCA accelerate this process. Similarly, TDP-43 and FUS form amyloid-like fibrils in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia, often through phase separation mechanisms. Understanding the regulation of fibril formation is critical for developing disease-modifying therapies.
Cancer
The tumor suppressor p16(INK4A) can undergo amyloid fibril formation upon oxidative stress, leading to its inactivation and potentially contributing to cancer progression. This links amyloid regulation to cell cycle control and tumor suppression. Additionally, other proteins involved in cancer, such as p53, can form amyloid aggregates under certain conditions, although the regulatory mechanisms are less understood.
Systemic Amyloidosis
Systemic amyloidoses, such as AA amyloidosis and AL amyloidosis, are caused by the deposition of amyloid fibrils in various organs. Serum amyloid A (SAA) is the precursor in AA amyloidosis, and N-terminal modifications can influence its amyloidogenicity. Transthyretin and immunoglobulin light chains are also involved in systemic amyloidoses. Regulation of fibril formation is a therapeutic target, with strategies aimed at stabilizing the native protein or inhibiting fibril growth.
Pigmentation Disorders
PMEL forms functional amyloid fibrils essential for melanin synthesis. Dysregulation of PMEL amyloid formation can lead to pigmentation disorders, such as hypopigmentation or hyperpigmentation. This highlights the dual nature of amyloid fibrils: while pathological in neurodegeneration, they can be physiologically beneficial in melanosomes.
From regulation of amyloid fibril formation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X regulate α-synuclein fibril formation? | SNCA knockout or overexpression in neuronal cell lines |
| How do point mutations affect amyloid fibril formation? | CRISPR point-mutation knock-in of disease-associated variants |
| What is the role of phase separation in fibril formation? | Knock-in of tagged FUS or hnRNPA1 for live-cell imaging |
| Can a candidate gene inhibit amyloid formation? | Overexpression of chaperone or regulatory gene in amyloid-prone cells |
| What is the effect of N-terminal modifications on SAA amyloidosis? | Knock-in of truncated or extended SAA1 variants |
| How does oxidative stress trigger p16 amyloid formation? | Point mutation of cysteine residues in CDKN2A |
How to Study the regulation of amyloid fibril formation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Thioflavin T fluorescence | Fibril formation kinetics | In vitro aggregation assays [1,6] |
| CRISPR knockout screen | Genes that regulate fibril formation | Genome-wide modifier screens |
| Live-cell imaging | Phase separation and fibril nucleation | Real-time visualization of FUS droplets |
| Mass spectrometry | Post-translational modifications | Detection of cysteine oxidation |
| Electron microscopy | Fibril morphology | Structural characterization |
| Circular dichroism | Secondary structure changes | Monitoring β-sheet formation |
| Dynamic light scattering | Oligomer size distribution | Nucleation studies |
| Fluorescence correlation spectroscopy | Diffusion and binding | Protein-protein interactions |
Thioflavin T Fluorescence Assays
Thioflavin T (ThT) is a fluorescent dye that binds to amyloid fibrils and exhibits enhanced fluorescence. ThT assays are widely used to monitor fibril formation kinetics in vitro, allowing researchers to measure lag time, elongation rate, and plateau. This method has been used to study the effect of charge on α-synuclein fibril formation and the role of N-terminal modifications in SAA amyloidogenesis.
CRISPR-Based Genetic Screens
CRISPR knockout and activation screens can identify genes that regulate amyloid fibril formation. For example, a genome-wide knockout screen in a cell model of α-synuclein aggregation can reveal modifiers of fibril formation. Diffusing protein binders can also be used to target intrinsically disordered proteins and modulate their aggregation.
Live-Cell Imaging of Phase Separation
Fluorescence microscopy of tagged proteins (e.g., FUS-GFP) can visualize liquid droplets and their transition to solid fibrils. This approach has been instrumental in linking phase separation to amyloid fibril formation. Time-lapse imaging allows real-time monitoring of droplet dynamics and fibril nucleation.
Proteomics and Mass Spectrometry
Mass spectrometry can identify post-translational modifications (e.g., oxidation) and map interaction partners of amyloidogenic proteins. For instance, cysteine oxidation of p16(INK4A) was detected by mass spectrometry, linking oxidative modification to fibril formation. Proteomic approaches can also quantify changes in protein abundance and solubility.
How CRISPR Can Be Used to Study GO:1905906 regulation of amyloid fibril formation
Knockout
CRISPR knockout (KO) is used to delete a candidate regulatory gene and assess its effect on amyloid fibril formation. For example, knocking out SNCA in neuronal cells abolishes α-synuclein aggregation, confirming its essential role. KO models are also valuable for studying the loss of function of chaperones or clearance factors.
Point Mutation
Point mutations can be introduced via CRISPR to mimic disease-associated variants or to probe specific residues. For instance, mutating cysteine residues in CDKN2A can prevent oxidative modification and subsequent amyloid formation. Point mutations in SNCA (e.g., A53T) are used to model familial Parkinson's disease.
Knock-in
Knock-in models allow the expression of a gene with a specific tag or mutation under endogenous regulatory control. Tagged knock-in of FUS or hnRNPA1 enables live-cell imaging of phase separation and fibril formation. Knock-in of N-terminal variants of SAA1 can model systemic amyloidosis.
Overexpression
Overexpression of a regulatory gene can test whether increased levels promote or inhibit amyloid fibril formation. For example, overexpressing a chaperone may suppress aggregation, while overexpressing a pro-amyloidogenic factor may accelerate it. Overexpression of PMEL in melanocytes can enhance functional amyloid formation.
How EDITGENE Supports regulation of amyloid fibril formation Research
Researchers studying regulation of amyloid fibril formation-related genes often need to determine whether a candidate gene is causally involved in the process or merely correlated. This requires precise genetic manipulation, which is where EDITGENE's CRISPR services can accelerate discovery.
Contact EDITGENE today to design your custom CRISPR model for regulation of amyloid fibril formation research.
Frequently Asked Questions About regulation of amyloid fibril formation
What is GO:1905906?
GO:1905906 is the Gene Ontology term for regulation of amyloid fibril formation, defined as any process that modulates the frequency, rate or extent of amyloid fibril formation.
What genes are involved in regulation of amyloid fibril formation?
Key genes include SNCA, CDKN2A, PMEL, SAA1, PTH, FUS, and HNRNPA1, among others [1,2,3,5,6,7].
How is amyloid fibril formation regulated?
It is regulated by charge, pH, post-translational modifications, proteolytic processing, phase separation, and chaperone activity [1,2,5,7].
What diseases are associated with amyloid fibril formation?
Neurodegenerative diseases (e.g., Parkinson's, ALS), cancer, systemic amyloidosis, and pigmentation disorders [1,2,3,5,6].
What methods are used to study regulation of amyloid fibril formation?
Thioflavin T fluorescence, CRISPR screens, live-cell imaging, mass spectrometry, and electron microscopy [1,2,4,5,6].
How can CRISPR be used to study amyloid fibril regulation?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise genetic manipulation to test causal roles.
What is the role of α-synuclein in amyloid fibril formation?
α-synuclein is a major component of Lewy bodies in Parkinson's disease, and its charge and mutations regulate fibril formation.
Can amyloid fibrils be functional?
Yes, PMEL forms functional amyloid fibrils essential for melanin synthesis in melanosomes.
What is the role of phase separation in amyloid fibril formation?
Liquid-liquid phase separation of RNA-binding proteins can precede and promote amyloid fibril formation.
How does oxidative stress affect amyloid fibril formation?
Oxidative modification, such as cysteine oxidation of p16(INK4A), can trigger amyloid fibril formation.
Conclusion
GO:1905906, regulation of amyloid fibril formation, is a critical biological process that controls the assembly of amyloid fibrils, which are central to numerous diseases and some normal physiological functions. The regulation occurs at multiple levels, from intrinsic protein properties to cellular quality-control systems. Key genes such as SNCA, CDKN2A, and PMEL have been shown to play pivotal roles, and advanced methods like CRISPR screening and live-cell imaging are unraveling the underlying mechanisms. Understanding this regulation offers promising avenues for therapeutic intervention in amyloid-related disorders.
References
- 1. Pálmadóttir T et al.. 2021. Charge Regulation during Amyloid Formation of α-Synuclein.. J Am Chem Soc 143(20):7777-7791 PMID: 33998793
- 2. Göbl C et al.. 2020. Cysteine oxidation triggers amyloid fibril formation of the tumor suppressor p16(INK4A).. Redox Biol 28:101316 PMID: 31539802
- 3. Bissig C et al.. 2016. PMEL Amyloid Fibril Formation: The Bright Steps of Pigmentation.. Int J Mol Sci 17(9) PMID: 27589732
- 4. Liu C et al.. 2025. Diffusing protein binders to intrinsically disordered proteins.. Nature 644(8077):809-817 PMID: 40739343
- 5. Lin Y et al.. 2015. Formation and Maturation of Phase-Separated Liquid Droplets by RNA-Binding Proteins.. Mol Cell 60(2):208-19 PMID: 26412307
- 6. Tanaka M et al.. 2023. Influences of amino-terminal modifications on amyloid fibril formation of human serum amyloid A.. Arch Biochem Biophys 742:109615 PMID: 37105512
- 7. Sachan S et al.. 2023. The pro-sequence of parathyroid hormone prevents premature amyloid fibril formation.. FEBS Lett 597(7):995-1006 PMID: 36700832
- 8. Liang Y et al.. 2026. Research Progress on the Regulation of Amyloid Fibril Formation in Cereal Proteins by Nonthermal Approaches.. J Agric Food Chem 74(20):15316-15334 PMID: 42127097
